SCHEMBL671000

SCHEMBL671000

CCCCCCCC(=O)NCCc1ccc(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 1.00
MAPT P10636 4/20 1.00
HSD17B10 Q99714 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
HPGD P15428 2/20 0.86
KDM4E B2RXH2 1/20 0.86
NPC1 O15118 1/20 0.86
GMNN O75496 1/20 0.86
USP2 O75604 1/20 0.86
LMNA P02545 1/20 0.86
TP53 P04637 1/20 0.86
CYP1A2 P05177 1/20 0.86
POLB P06746 1/20 0.86
CYP3A4 P08684 1/20 0.86
CYP2C9 P11712 1/20 0.86
IDE P14735 1/20 0.86
ALOX15 P16050 1/20 0.86
NFKB1 P19838 1/20 0.86
MAPK1 P28482 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617723 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30368905 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30718914 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30718949 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
Palmitoyl Dopamine SCHEMBL30438287 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
Palmitoyl Dopamine SCHEMBL875454 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL30582326 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL10617939 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL3326638 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A
SCHEMBL3325854 1.00 TRPV1 (1.00) TRPV1MAPTHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3689852-B1 METHOD FOR PRODUCING DIHYDROXYINDOLES KAO CORP (JP) 2024-05-29 EP claimed
EP-3689852-B1 METHOD FOR PRODUCING DIHYDROXYINDOLES KAO CORP (JP) 2024-05-29 EP disclosed
US-20230323168-A1 CATECHOL MODIFIERS FOR EPOXY ADHESIVES ZYMERGEN INC. 2023-10-12 US disclosed
US-10947194-B2 Method for producing dihydroxyindoles KAO CORPORATION (JP) 2021-03-16 US disclosed
US-20200339510-A1 METHOD FOR PRODUCING DIHYDROXYINDOLES KAO CORPORATION (JP) 2020-10-29 US disclosed
EP-2914575-B1 PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF UNIV MICHIGAN REGENTS (US) 2020-10-14 EP disclosed
EP-3705473-A1 PRODUCTION METHOD FOR DIHYDROXYINDOLES Kao Corporation (JP) 2020-09-09 EP disclosed
EP-3689852-A1 METHOD FOR PRODUCING DIHYDROXYINDOLES Kao Corporation (JP) 2020-08-05 EP disclosed
CN-111247124-A Process for producing dihydroxyindoles 花王株式会社 2020-06-05 CN disclosed
CN-111225902-A Process for producing dihydroxyindoles 花王株式会社 2020-06-02 CN disclosed
US-20140221485-A1 LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE NOVALIQ GMBH (DE) 2014-08-07 US disclosed
WO-2014070983-A1 PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-05-08 WO disclosed
EP-2605754-A1 COMPOSITIONS AND METHODS FOR IMPROVED ORGAN TRANSPLANT PRESERVATION AND ACCEPTANCE Novaliq GmbH (DE) 2013-06-26 EP disclosed
US-20130142866-A1 COMPOSITIONS AND METHODS FOR IMPROVED ORGAN TRANSPLANT PRESERVATION AND ACCEPTANCE NOVALIQ GMBH (DE) 2013-06-06 US disclosed
WO-2013034457-A1 LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE NOVALIQ GMBH (DE) 2013-03-14 WO disclosed
WO-2013034457-A1 LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE NOVALIQ GMBH (DE) 2013-03-14 WO disclosed
EP-2422769-A1 Compositions and methods for improved organ transplant preservation and acceptance Novaliq GmbH (DE) 2012-02-29 EP disclosed
WO-2012022737-A1 COMPOSITIONS AND METHODS FOR IMPROVED ORGAN TRANSPLANT PRESERVATION AND ACCEPTANCE NOVALIQ GMBH (DE) 2012-02-23 WO disclosed
EP-2187735-A2 SUBSTANCES FOR THE PROTECTION OF CELLS AND/OR TISSUES Lösel, Ralf (DE) 2010-05-26 EP disclosed
WO-2009015752-A2 SUBSTANCES FOR THE PROTECTION OF CELLS AND/OR TISSUES LOESEL RALF (DE) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221485-A1 LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE SLC6A3, SLC6A2, DRD2 TRPV1 431/4885MAPT 1668/4885HSD17B10 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.